Why can symptoms briefly worsen when starting leuprolide?

As a GnRH agonist it first stimulates the pituitary, causing a short testosterone/estrogen flare before receptor desensitization suppresses hormone levels.

What are the main long-term risks?

Chronic hypogonadism causes hot flushes and bone mineral density loss; in men on androgen deprivation there are also cardiometabolic considerations.

How is leuprolide given?

Only as a clinician-administered depot injection (monthly to 6-monthly) or pediatric implant; it is not taken orally or self-administered casually.

Can bone loss and hot flushes be reduced?

In women, estrogen/progestin add-back therapy limits bone loss and vasomotor symptoms during longer courses, and bone health should be monitored.

EMA-approvedaka Leuprorelin, Lupron, Eligard

Leuprolide — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Leuprolide (also known as Leuprorelin) is a peptide catalogued under Sexual Health (GnRH agonist). It is described as: GnRH receptor agonist. Documented context: Prostate cancer; endometriosis; precocious puberty. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Leuprolide?

Leuprolide (leuprolide acetate; brands include Lupron, Eligard) is a synthetic long-acting gonadotropin-releasing hormone (GnRH) agonist and one of the most established drugs in its class.

It is FDA- and EMA-approved as a human therapeutic for advanced/metastatic prostate cancer, endometriosis, uterine fibroids (often with iron for associated anemia), and central precocious puberty; it is not a research peptide for enhancement.

Evidence level is high: its indications are supported by randomized controlled trials and decades of clinical use.

How does Leuprolide work?

Continuous (rather than pulsatile) GnRH-receptor stimulation initially raises LH/FSH and sex steroids, then downregulates and desensitizes pituitary GnRH receptors.

Sustained receptor desensitization suppresses LH/FSH secretion, driving testosterone (men) and estrogen (women) to castrate or postmenopausal levels.

What does the research say about Leuprolide?

In metastatic prostate cancer, leuprolide achieves medical castration with efficacy comparable to diethylstilbestrol but with fewer cardiovascular side effects. ^[1]
For central precocious puberty, GnRH-agonist therapy including leuprolide halts pubertal progression and can preserve adult-height potential when started early. ^[2]
In endometriosis, leuprolide depot relieves pelvic pain, and hormonal add-back preserves bone density and reduces vasomotor symptoms over 12 months. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Leuprolide versus diethylstilbestrol for metastatic prostate cancer — Leuprolide Study Group, New England Journal of Medicine 1984. (Randomized controlled trial)
[2] Consensus statement on the use of gonadotropin-releasing hormone analogs in children — Carel JC et al., Pediatrics 2009. (Consensus statement / expert review)
[3] Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study — Hornstein MD et al., Obstetrics and Gynecology 1998. (Randomized controlled trial)
[4] A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata — Friedman AJ et al., Fertility and Sterility 1989. (Randomized controlled trial)
[5] Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study — Friedman AJ et al., Obstetrics and Gynecology 1991. (Randomized controlled trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Leuprolide is given only as clinician-administered depot injections (for example monthly, 3-, 4-, or 6-month intramuscular or subcutaneous formulations) or, historically, a pediatric implant; formulation and dose differ by indication.

This is context only and not a dosing recommendation; regimens must be individualized and prescribed by a qualified clinician.

Side effects & safety profile

Because of the agonist mechanism, therapy begins with a transient testosterone/estrogen flare (roughly the first 1-2 weeks) that can temporarily worsen prostate-cancer symptoms such as bone pain or urinary obstruction before suppression sets in.

The dominant class effects reflect hypogonadism: hot flushes and vasomotor symptoms, and with prolonged use loss of bone mineral density; in men on androgen-deprivation therapy there are also cardiometabolic considerations including weight gain, insulin resistance, and possible cardiovascular risk.

It is a prescription-only drug requiring clinician supervision, baseline and periodic monitoring, and is contraindicated in pregnancy.

Stacking & combinations

In prostate cancer an anti-androgen such as bicalutamide is commonly co-administered around initiation to blunt the testosterone flare; in women, estrogen/progestin add-back therapy is used to limit bone loss and vasomotor symptoms during longer courses.

Finding Leuprolide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a fully approved prescription medicine (FDA/EMA) for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, backed by randomized trials.

References

[1] Leuprolide versus diethylstilbestrol for metastatic prostate cancer — Leuprolide Study Group, New England Journal of Medicine 1984. PMID: 6436700. View sourceStudy: Randomized controlled trialLeuprolide produced comparable objective response and survival to diethylstilbestrol with fewer cardiovascular adverse effects.
[2] Consensus statement on the use of gonadotropin-releasing hormone analogs in children — Carel JC et al., Pediatrics 2009. PMID: 19332438. View sourceStudy: Consensus statement / expert reviewGnRH agonists effectively suppress the HPG axis in central precocious puberty and can improve adult height when initiated at a young age.
[3] Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study — Hornstein MD et al., Obstetrics and Gynecology 1998. PMID: 9464714. View sourceStudy: Randomized controlled trialNorethindrone-based add-back preserved bone density and reduced vasomotor symptoms while maintaining pain relief over 12 months of leuprolide therapy.
[4] A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata — Friedman AJ et al., Fertility and Sterility 1989. PMID: 2492232. View sourceStudy: Randomized controlled trialLeuprolide depot significantly reduced uterine and fibroid volume versus placebo.
[5] Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study — Friedman AJ et al., Obstetrics and Gynecology 1991. PMID: 1901638. View sourceStudy: Randomized controlled trialLeuprolide depot reduced uterine and fibroid volume and symptoms, with regrowth after discontinuation.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.